EPISODE · Jul 9, 2021 · 30 MIN
Treatment of Relapsed/Refractory Hodgkin's Lymphoma
from IMPACT Medicom
In this episode of our podcast, we are joined by a very special guest, Dr. John Kuruvilla, who is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto. We discuss:The current treatment of classical Hodgkin’s Lymphoma The use of checkpoint inhibitors for these patients Results of the KEYNOTE-204 trial, a randomized phase III trial of pembrolizumab versus brentuximab vedotin in relapsed or refractory Hodgkin’s LymphomaHow future research will address some key questions in this areaThis podcast episode is sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Embed this episode
What this episode covers
In this episode of our podcast, we are joined by a very special guest, Dr. John Kuruvilla, who is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto. We discuss: The current treatment of classical Hodgkin’s Lymphoma The use of checkpoint inhibitors for these patients Results of the KEYNOTE-204 trial, a randomized phase III trial of pembrolizumab ...
NOW PLAYING
Treatment of Relapsed/Refractory Hodgkin's Lymphoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.